Regencell Bioscience Holdings Ltd (RGC) Market Cap, Revenue and SEC Filings - Developers Digest

← All companies

R

Regencell Bioscience Holdings Ltd

RGC - CIK 0001829667

Market cap$10.11 B

Rank#936

SEC filings82

Regencell Bioscience Holdings Ltd trades as RGC and has a market capitalization of $10.11 B, making it the #936 largest US-listed company by market value. This page tracks Regencell Bioscience Holdings Ltd through 82 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Net income (latest FY)-$3.58MFY 2025

Operating cash flow (latest FY)-$3.11MFY 2025

Total assets (latest FY)$5.76MFY 2025

Financial performance

RGC annual net incomeView details

RGC operating cash flowView details

Key statistics

Market cap: $10.11 B
Share price (derived)market cap / shares outstanding: $20.45
EPS (diluted)FY 2025: $-0.72
Shares outstandingas of 2025-06-30: 0.49B
Total equityas of 2025-06-30: $4.86M
Return on equity: -73.7%
Current ratioas of 2025-06-30: 7.39
R&D expenseFY 2025: $948.29K

Latest filings

Filing	Type	Filed
6-K	-	2026-05-22
Prospectus supplement	424B5	2026-05-19
6-K	-	2026-05-19
6-K	-	2026-05-19
6-K	-	2026-05-08
6-K	-	2026-04-17
6-K	-	2026-03-30
6-K	-	2026-03-30

Browse the full filing history (82 filings)

Recent press releases

Similar companies

The largest companies sharing Regencell Bioscience Holdings Ltd's SEC industry classification (medicinal chemicals & botanical products).

CURLFCuraleaf$2.85 B RGC vs CURLF

DFTXDefinium Therapeutics, Inc.$2.53 B RGC vs DFTX

CRONCronos Group Inc.$1.03 B RGC vs CRON

Frequently asked questions

What is Regencell Bioscience Holdings Ltd's market cap?

Regencell Bioscience Holdings Ltd (RGC) has a market capitalization of $10.11 B as of 2026-06-10, ranking #936 among US-listed companies.

Is Regencell Bioscience Holdings Ltd profitable?

In its latest fiscal year Regencell Bioscience Holdings Ltd reported a net loss of $3.58M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.